[1]JournalofMedicinalChemistry,2006,vol.49,p.6510-6521
[2]Patent:CN104177288,2020,B.Locationinpatent:Paragraph0169-0171
[3]BioMetals,2016,vol.29,p.157-170
[4]InternationalJournalofMolecularSciences,2016,vol.17
[5]Patent:CN104844632,2017,B.Locationinpatent:Paragraph0033;0034;0035;0036;0037;0051-0052;0054-0055
[6]EuropeanJournalofMedicinalChemistry,2019,vol.171,p.180-194
[1]Akladios,FadyN.;Andrew,ScottD.;Parkinson,ChristopherJ.[BioMetals,2016,vol.29,#1,p.157-170]
[1]Akladios,FadyN.;Andrew,ScottD.;Parkinson,ChristopherJ.[BioMetals,2016,vol.29,#1,p.157-170]
[1]Stacy,AlexandraE.;Palanimuthu,Duraippandi;Bernhardt,PaulV.;Kalinowski,DanutaS.;Jansson,PatricJ.;Richardson,DesR.[JournalofMedicinalChemistry,2016,vol.59,#10,p.4965-4984]
Title: The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
Journal: The Journal of biological chemistry 20141128
Title: Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
Journal: Biochemical pharmacology 20141001
Title: The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
Journal: The Journal of biological chemistry 20140404
Title: The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20130201
Title: Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Journal: Bioorganic & medicinal chemistry letters 20120901
Title: Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
Journal: Journal of medicinal chemistry 20120823
Title: The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Journal: Biochemical pharmacology 20120701
Title: Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Journal: Molecular pharmacology 20120701
Title: The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
Journal: The Journal of biological chemistry 20120518
Title: Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.
Journal: British journal of pharmacology 20120101
Title: Investigation of substituted 6-aminohexanoates as skin penetration enhancers.
Journal: Bioorganic & medicinal chemistry 20120101
Title: The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.
Journal: Cancer chemotherapy and pharmacology 20111101
Title: Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity.
Journal: Journal of medicinal chemistry 20111013
Title: Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.
Journal: Cancer research 20110901
Title: The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Journal: Molecular pharmacology 20110601
Title: Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1.
Journal: The Journal of biological chemistry 20110429
Title: Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.
Journal: Molecular pharmacology 20110101
Title: Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.
Journal: Bioorganic & medicinal chemistry 20101215
Title: Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status.
Journal: Cancer letters 20101208
Title: The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.
Journal: Journal of inorganic biochemistry 20101101
Title: Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
Journal: Journal of medicinal chemistry 20100812
Title: Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Journal: Journal of medicinal chemistry 20100211
Title: 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
Journal: Journal of medicinal chemistry 20090312
Title: Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Journal: American journal of hematology 20090301
Title: The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
Journal: Cancer research 20090201
Title: Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
Journal: Journal of medicinal chemistry 20090122
Title: HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115
Title: Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.
Journal: BMC medical genomics 20090101
Title: Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Journal: Journal of medicinal chemistry 20080124
Title: Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
Journal: Journal of medicinal chemistry 20071129
Title: Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Journal: Journal of medicinal chemistry 20070726
Title: Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity.
Journal: Journal of pharmaceutical and biomedical analysis 20070312
Title: Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
Journal: Journal of medicinal chemistry 20061102
Title: Rao VA, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009 Feb 1;69(3):948-57.
Title: Lovejoy DB, et al. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 2011 Sep 1;71(17):5871-80.
